Pacira BioSciences (NASDAQ:PCRX) Receives Sector Perform Rating from Royal Bank of Canada

Royal Bank of Canada reiterated their sector perform rating on shares of Pacira BioSciences (NASDAQ:PCRX) in a report released on Tuesday,Benzinga reports. Royal Bank of Canada currently has a $18.00 price target on the stock.

Other equities research analysts have also recently issued research reports about the stock. Barclays decreased their target price on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 12th. Needham & Company LLC increased their price objective on Pacira BioSciences from $22.00 to $30.00 and gave the company a “buy” rating in a report on Monday. Jefferies Financial Group boosted their target price on Pacira BioSciences from $15.00 to $18.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th. Finally, HC Wainwright reiterated a “buy” rating and issued a $39.00 price target on shares of Pacira BioSciences in a research note on Wednesday, December 4th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $24.50.

Pacira BioSciences Stock Performance

PCRX stock opened at $20.55 on Tuesday. Pacira BioSciences has a one year low of $11.16 and a one year high of $34.01. The firm has a market cap of $948.86 million, a price-to-earnings ratio of -10.12 and a beta of 0.76. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The firm has a 50-day simple moving average of $18.43 and a two-hundred day simple moving average of $17.49.

Institutional Trading of Pacira BioSciences

Several large investors have recently added to or reduced their stakes in PCRX. CWM LLC raised its stake in shares of Pacira BioSciences by 713.6% in the third quarter. CWM LLC now owns 6,517 shares of the company’s stock worth $98,000 after purchasing an additional 5,716 shares during the last quarter. Virtus Investment Advisers Inc. acquired a new position in Pacira BioSciences in the 3rd quarter worth approximately $98,000. Quest Partners LLC purchased a new position in Pacira BioSciences during the 2nd quarter worth approximately $113,000. China Universal Asset Management Co. Ltd. lifted its stake in Pacira BioSciences by 62.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company’s stock valued at $134,000 after acquiring an additional 3,404 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new stake in shares of Pacira BioSciences in the 2nd quarter valued at $140,000. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.